Skip to main content

Advertisement

Table 2 Posted results of first-line combination regimen trials for pembrolizumab, nivolumab, and atezolizumab in advanced NSCLC

From: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Identifier Trials Agent Phase Population Arms Biomarkers ORR mPFS 1 year
PFS rate
mOS 1 year OS rate mDOR Adverse Effects Rate (≥ grade 3)
NCT02039674 Keynote 021 Pembrolizumab II Untreated metastatic
Non-squamous NSCLC
Without EGFR/ALK alteration
Pembrolizumab + platinum Regardless PD-L1 55.00% 24 m NA NR NA NA 39.00%
Platinum 29.00% 9.3 m 21.1 m 26.00%
NCT02578680 Keynote 189 Pembrolizumab III Untreated metastatic
Non-squamous NSCLC
Without EGFR/ALK alteration
Pembrolizumab + platinum Regardless PD-L1 47.60% 8.8 m 34.10% NR 69.20% 11.2 m 67.20%
Platinum 18.90% 4.9 m 17.30% 11.3 m 49.90% 7.8 m 65.80%
NCT02775435 Keynote 407 Pembrolizumab III Untreated metastatic, squamous NSCLC Pembrolizumab + platinum Regardless PD-L1 57.90% 6.4 m NA 15.9 m 65.20% 7.7 m 69.80%
platinum 38.40% 4.8 m NA 11.3 m 48.30% 4.8 m 68.20%
NCT02477826 Checkmate 227 Nivolumab III Untreated metastatic
Non-squamous NSCLC
Without EGFR/ALK alteration
Nivolumab + platinum TMB ≥ 10mut/Mb 60.50% NA 27.00% NA NA NA NA
Nivolumab + ipilimumab 45.30% 7.2 m 45.00% 31.20%
Platinum 27.00% 5.4 m 13.20% 36.10%
NCT02657434 Impower 131 Atezolizumab III Treatment-naïve Stage IV squamous NSCLC Atezolizumoab + carboplatin ITT population 49.00% 6.3 m 24.00% 14.0 m 55.60% NA 69.00%
Carboplatin 41.00% 5.6 m 12.00% 13.9 m 56.80% 58.00%
2NCT02657434 Impower132 Atezolizumab12 III Non-squamous NSCLC
Without EGFR/ALK
alterationUntreated metastatic
Atezolizumoab + carboplatin ITT population 47.00% 7.6 m 33.70% 18.1 m 59.60% 10.1 m 69.00%
Carboplatin 32.00% 5.2 m 13.6 m 59.00%
NCT02659059 Checkmate 568 Nivolumab II Untreated metastatic
Non-squamous NSCLC
Without EGFR/ALK alteration
Nivolumab plus low-dose ipilimumab PD-L1 < 1% 41.00% 6.8 m 52%a NA NA NA 29.00%
PD-L1 ≥ 1% 15.00% 2.8 m 32%a     
TMB ≥ 10 mut/Mb 44.00% 7.1 m 55%a     
TMb < 10 mut/Mb 12.00% 2.6 m 31%a     
  1. Combination strategies may help patients overcome NSCLC resistance that ICI monotherapy face with
  2. ORR objective response rate, PFS Progression Free Survival, OS overall survival, DOR Duration of Response, ITT intend to treat, TMB tumor mutation burden
  3. a6-month PFS rate